ATC Group: C01CE03 Enoximone

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of C01CE03 in the ATC hierarchy

Level Code Title
1 C Cardiovascular system
2 C01 Cardiac therapy
3 C01C Cardiac stimulants excl. cardiac glycosides
4 C01CE Phosphodiesterase inhibitors
5 C01CE03 Enoximone

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
PAREN - Parenteral 1 g

Active ingredients in C01CE03

Active Ingredient Description
Enoximone

Enoximone, an imidazolone, has both positive inotropic and vasolidator properties, inhibiting cardiac phosphodiesterase III with an increase in cAMP.

Related product monographs

Title Information Source Document Type  
PERFAN Concentrate for solution for injection or infusion Health Products Regulatory Authority (IE) MPI, EU: SmPC

Medicines in this ATC group

France (FR)

Malta (MT)

Netherlands (NL)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.